Conferences & Events

Found 121,725 articles

• PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

  4/23/2024

  PharmAbcine, Inc. announced that the Company's U.S. subsidiary, Wincal Biopharm, Inc., will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology, the world's largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States.

• Vizient conducts first Insight: Cell, Gene, and Specialty Pharmacy Symposium

  4/23/2024

  Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss the promise and unique challenges of the rapidly expanding market of cell, gene and other advanced therapies.

• Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue

  4/23/2024

  Medivir AB announced an update from a Type C meeting with the FDA, regarding the company's plans for a global phase 2b study and opening of an IND for fostroxacitabine bralpamide in the US.

• AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting

  4/23/2024

  AAVantgarde Bio announces the publication of an abstract accepted as an oral presentation submitted to The American Society of Gene & Cell Therapy 27th Annual Meeting, to be held May 7-11 in Baltimore.

• Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

  4/23/2024

  Century Therapeutics today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.

• Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

  4/23/2024

  Omega Therapeutics, Inc. medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024.

• Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

  4/23/2024

  Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET.

• 908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024

  4/23/2024

  908 Devices Inc. today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

• BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients

  4/23/2024

  BiomX Inc. today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April.

• Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

  4/23/2024

  Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets.

• Tome Biosciences to Present Data on Programmable Genomic Integration Technologies at ASGCT

  4/23/2024

  Tome Biosciences, Inc. today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.

• PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

  4/23/2024

  Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial.

• Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

  4/23/2024

  Prime Medicine, Inc. today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting.

• Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

  4/23/2024

  Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.

• Electromed, Inc. Schedules its Third Quarter Fiscal 2024 Financial Results Conference Call for May 7, 2024 at 5:00 p.m. ET

  4/23/2024

  Electromed, Inc. today announced that it will issue its financial results press release for the fiscal 2024 third quarter ended March 31, 2024, on May 7, 2024 after the close of the stock market.

• Halozyme to Report First Quarter 2024 Financial and Operating Results

  4/23/2024

  Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.

• PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

  4/23/2024

  PROCEPT BioRobotics today announced that 12 abstracts highlighting its Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas, from May 3 - 6, 2024.

• Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and SynBioBeta Global Synthetic Biology Conference

  4/23/2024

  Dyno Therapeutics, Inc. today announced a Scientific Symposium and the presentation of three research abstracts, including one oral presentation, at the upcoming 27th Annual Congress of the American Society of Gene & Cell Therapy (ASGCT) being held May 7-11th, 2024 in Baltimore, Maryland.

• Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

  4/23/2024

  Rezolute, Inc. today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.

• Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7

  4/23/2024

  Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024.